Equine gastric disease treatment moves toward lesion-specific care

A new educational push around equine gastric disease is spotlighting a familiar problem with a more refined message: treatment has to match the lesion. In a March 9, 2026, article, The Horse said successful treatment depends on accurate diagnosis, pharmacologic therapy, and management changes, echoing a wider shift in equine medicine away from treating all gastric ulcers as a single entity. (thehorse.com)

That shift has been building for years. UC Davis’ Center for Equine Health notes that what was once grouped under equine gastric ulcer syndrome is now divided into ESGD and EGGD, a distinction formalized in 2009 as clinicians recognized that the squamous and glandular regions differ in anatomy, pathophysiology, and response to therapy. ESGD is more strongly linked to acid exposure and management factors such as forage timing, carbohydrate load, and exercise, while EGGD appears more closely tied to stress, individual susceptibility, and other less clearly defined factors. (cehhorsereport.vetmed.ucdavis.edu)

That matters because the treatment evidence is uneven across the two conditions. UC Davis states that omeprazole is the only FDA-approved treatment for equine gastric ulcers in the U.S., and prescribing information for GastroGard says a 28-day course at 4 mg/kg healed or reduced ulcer severity in 92% of treated horses. But that strong performance applies mainly to squamous disease. Expert commentary reported by The Horse says most horses with ESGD respond to omeprazole alone, whereas only about 25% of horses with glandular ulcers do. For EGGD, clinicians often combine omeprazole with sucralfate and, in some cases, misoprostol. (cehhorsereport.vetmed.ucdavis.edu)

Recent research adds another layer: recurrence and monitoring remain unresolved. A 2025 blinded, randomized, placebo-controlled trial published in Equine Veterinary Journal evaluated a nutraceutical containing lecithin, pectin, and meadowsweet after omeprazole treatment in 30 horses. The supplement did not significantly prevent recurrence of squamous or glandular disease on gastroscopy, although investigators did report changes in salivary biomarkers that could suggest effects on mucosal health. That’s useful, but it stops short of proving a clinically meaningful preventive benefit. (pubmed.ncbi.nlm.nih.gov)

There’s also growing interest in how gastric disease presents clinically. A 2025 Animals paper described a possible “behavioral signature” of gastric discomfort, including repeated attention to the abdomen during feeding-related contexts, while a 2025 clinical commentary argued that behavioral medicine may have a place in multimodal chronic EGUS management. Taken together, those papers suggest clinicians may increasingly look beyond classic physical signs, even though gastroscopy still remains the only definitive way to diagnose lesion presence, type, and severity. (mdpi.com)

Industry and expert messaging is also converging on a practical point: management changes are not optional add-ons. The Horse cited Ben Sykes and Amanda Browne stressing that forage access, alfalfa before exercise, carbohydrate management, stress reduction, rest days, and investigation of other pain sources all shape outcomes. Their comments also highlighted a treatment nuance that can affect results in practice: feeding reduces omeprazole absorption, so administration timing may need more attention than some pet parents and barn managers expect. (thehorse.com)

Why it matters: For veterinary professionals, this is a reminder to resist empiric “ulcer treatment” as a catch-all label. Horses with vague performance decline, appetite changes, or behavior changes may still need a full workup, and when gastric disease is suspected, gastroscopy remains the best way to separate ESGD from EGGD and guide therapy. It also reinforces the limits of nutraceuticals and the importance of setting expectations with pet parents: healing can take weeks, recurrence is common without management change, and glandular disease may require a longer, more individualized plan than squamous disease. (cehhorsereport.vetmed.ucdavis.edu)

What to watch: The next phase of this story is likely to center on better EGGD-specific protocols, more rigorous evidence for adjunctive products, and whether salivary biomarkers or behavior-based assessment can become useful clinical tools between gastroscopies. For now, the standard of care still points back to the same foundation: diagnose accurately, treat the lesion type in front of you, and address the management conditions that helped create it. (pubmed.ncbi.nlm.nih.gov)